Concepts (190)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thyroid Gland | 3 | 2021 | 355 | 1.790 |
Why?
|
| Thyroid Neoplasms | 7 | 2022 | 1866 | 1.740 |
Why?
|
| Graves Ophthalmopathy | 2 | 2021 | 22 | 0.960 |
Why?
|
| Lacrimal Apparatus Diseases | 5 | 2020 | 137 | 0.840 |
Why?
|
| Multidetector Computed Tomography | 2 | 2022 | 150 | 0.800 |
Why?
|
| Exophthalmos | 1 | 2021 | 45 | 0.800 |
Why?
|
| Parathyroid Glands | 1 | 2021 | 127 | 0.770 |
Why?
|
| Orbit | 2 | 2021 | 205 | 0.760 |
Why?
|
| Parathyroid Neoplasms | 1 | 2022 | 185 | 0.760 |
Why?
|
| Meningeal Carcinomatosis | 2 | 2017 | 31 | 0.750 |
Why?
|
| Orbital Neoplasms | 6 | 2021 | 224 | 0.740 |
Why?
|
| Optic Nerve Diseases | 1 | 2021 | 103 | 0.730 |
Why?
|
| Submandibular Gland Neoplasms | 1 | 2020 | 37 | 0.720 |
Why?
|
| Four-Dimensional Computed Tomography | 1 | 2020 | 226 | 0.660 |
Why?
|
| Magnetic Resonance Imaging | 14 | 2020 | 7702 | 0.650 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2020 | 341 | 0.620 |
Why?
|
| Tomography, X-Ray Computed | 14 | 2020 | 7551 | 0.620 |
Why?
|
| Adenoma | 1 | 2022 | 716 | 0.600 |
Why?
|
| Fascia | 2 | 2014 | 68 | 0.550 |
Why?
|
| Meningeal Neoplasms | 1 | 2020 | 441 | 0.550 |
Why?
|
| Eye Neoplasms | 4 | 2020 | 247 | 0.520 |
Why?
|
| Diagnostic Imaging | 3 | 2021 | 1162 | 0.510 |
Why?
|
| Thyroid Carcinoma, Anaplastic | 1 | 2017 | 259 | 0.510 |
Why?
|
| Ultrasonography | 3 | 2020 | 1863 | 0.490 |
Why?
|
| Neuroimaging | 1 | 2017 | 403 | 0.480 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2019 | 925 | 0.460 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2020 | 716 | 0.460 |
Why?
|
| Spinal Neoplasms | 1 | 2019 | 631 | 0.460 |
Why?
|
| Dermatofibrosarcoma | 1 | 2013 | 72 | 0.450 |
Why?
|
| Maxillofacial Abnormalities | 1 | 2011 | 11 | 0.410 |
Why?
|
| Erdheim-Chester Disease | 1 | 2011 | 53 | 0.390 |
Why?
|
| Middle Aged | 32 | 2021 | 86204 | 0.380 |
Why?
|
| Spinal Diseases | 1 | 2011 | 125 | 0.380 |
Why?
|
| Head and Neck Neoplasms | 5 | 2019 | 3976 | 0.370 |
Why?
|
| Aged | 29 | 2021 | 70117 | 0.370 |
Why?
|
| Biopsy, Fine-Needle | 3 | 2020 | 690 | 0.360 |
Why?
|
| Neck | 1 | 2012 | 383 | 0.360 |
Why?
|
| Oculomotor Muscles | 2 | 2021 | 179 | 0.340 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2011 | 388 | 0.330 |
Why?
|
| Immunocompromised Host | 2 | 2017 | 698 | 0.330 |
Why?
|
| Adult | 27 | 2021 | 77950 | 0.320 |
Why?
|
| Brain Diseases | 1 | 2011 | 403 | 0.310 |
Why?
|
| Male | 34 | 2021 | 123000 | 0.310 |
Why?
|
| Ulcer | 1 | 2008 | 78 | 0.310 |
Why?
|
| Soft Tissue Injuries | 1 | 2008 | 51 | 0.310 |
Why?
|
| Nasal Septum | 1 | 2007 | 47 | 0.300 |
Why?
|
| Humans | 46 | 2022 | 261506 | 0.300 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2020 | 10035 | 0.290 |
Why?
|
| Female | 33 | 2021 | 141928 | 0.290 |
Why?
|
| Postoperative Complications | 3 | 2019 | 5542 | 0.290 |
Why?
|
| Retrospective Studies | 22 | 2021 | 37905 | 0.290 |
Why?
|
| Abscess | 1 | 2007 | 177 | 0.280 |
Why?
|
| Young Adult | 11 | 2021 | 21445 | 0.260 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 2007 | 285 | 0.250 |
Why?
|
| Orbit Evisceration | 2 | 2014 | 46 | 0.240 |
Why?
|
| Carcinoma, Papillary | 3 | 2021 | 584 | 0.230 |
Why?
|
| Positron-Emission Tomography | 6 | 2017 | 2173 | 0.220 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 2 | 2017 | 301 | 0.220 |
Why?
|
| Lymph Nodes | 3 | 2019 | 2967 | 0.210 |
Why?
|
| Carcinoma, Adenoid Cystic | 2 | 2020 | 421 | 0.210 |
Why?
|
| Skin Neoplasms | 2 | 2021 | 4654 | 0.210 |
Why?
|
| Thyroglossal Cyst | 1 | 2021 | 14 | 0.210 |
Why?
|
| Sarcoma | 1 | 2011 | 1725 | 0.190 |
Why?
|
| Sensitivity and Specificity | 2 | 2020 | 4971 | 0.190 |
Why?
|
| Mixed Tumor, Malignant | 1 | 2020 | 19 | 0.190 |
Why?
|
| Radiotherapy | 1 | 2008 | 1824 | 0.190 |
Why?
|
| Adenoma, Pleomorphic | 1 | 2020 | 63 | 0.190 |
Why?
|
| Optic Nerve | 1 | 2021 | 133 | 0.180 |
Why?
|
| Radiation Injuries | 1 | 2008 | 1411 | 0.180 |
Why?
|
| Radiography | 2 | 2019 | 1904 | 0.180 |
Why?
|
| Calcitonin | 1 | 2020 | 186 | 0.170 |
Why?
|
| Retinal Neoplasms | 1 | 2021 | 144 | 0.170 |
Why?
|
| Retinoblastoma | 1 | 2021 | 200 | 0.170 |
Why?
|
| Algorithms | 2 | 2020 | 3890 | 0.170 |
Why?
|
| Aged, 80 and over | 9 | 2020 | 29902 | 0.170 |
Why?
|
| Multimodal Imaging | 2 | 2014 | 550 | 0.170 |
Why?
|
| Brain Neoplasms | 4 | 2009 | 4849 | 0.160 |
Why?
|
| Lacrimal Apparatus | 1 | 2020 | 181 | 0.160 |
Why?
|
| Rhabdomyosarcoma | 1 | 2021 | 341 | 0.160 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2021 | 5437 | 0.160 |
Why?
|
| Particle Accelerators | 1 | 2020 | 352 | 0.160 |
Why?
|
| Orbital Cellulitis | 1 | 2017 | 18 | 0.160 |
Why?
|
| Sarcoma, Ewing | 1 | 2021 | 406 | 0.150 |
Why?
|
| Oropharyngeal Neoplasms | 2 | 2019 | 1105 | 0.150 |
Why?
|
| Plasmacytoma | 1 | 2018 | 111 | 0.150 |
Why?
|
| Spine | 1 | 2019 | 293 | 0.150 |
Why?
|
| Positron Emission Tomography Computed Tomography | 2 | 2020 | 833 | 0.150 |
Why?
|
| Image-Guided Biopsy | 1 | 2019 | 327 | 0.150 |
Why?
|
| Eye Infections, Bacterial | 1 | 2017 | 96 | 0.150 |
Why?
|
| Thyroidectomy | 1 | 2020 | 486 | 0.150 |
Why?
|
| ROC Curve | 1 | 2020 | 1183 | 0.140 |
Why?
|
| Neurilemmoma | 1 | 2017 | 127 | 0.140 |
Why?
|
| Ultrasonography, Interventional | 1 | 2019 | 429 | 0.140 |
Why?
|
| Conjunctival Neoplasms | 1 | 2017 | 120 | 0.140 |
Why?
|
| Adolescent | 8 | 2021 | 31252 | 0.130 |
Why?
|
| Tertiary Care Centers | 1 | 2017 | 403 | 0.130 |
Why?
|
| Lymphatic Metastasis | 3 | 2019 | 4844 | 0.130 |
Why?
|
| Vision Disorders | 1 | 2017 | 245 | 0.130 |
Why?
|
| Phantoms, Imaging | 1 | 2020 | 1271 | 0.130 |
Why?
|
| Myocutaneous Flap | 1 | 2014 | 30 | 0.120 |
Why?
|
| Diagnosis, Differential | 3 | 2017 | 4744 | 0.110 |
Why?
|
| Skin Transplantation | 1 | 2014 | 173 | 0.110 |
Why?
|
| Software | 1 | 2020 | 1321 | 0.110 |
Why?
|
| Retropharyngeal Abscess | 1 | 2012 | 11 | 0.110 |
Why?
|
| Logistic Models | 1 | 2020 | 3441 | 0.110 |
Why?
|
| Pharyngeal Neoplasms | 1 | 2013 | 133 | 0.110 |
Why?
|
| Lipoma | 1 | 2012 | 89 | 0.110 |
Why?
|
| Neoplasms, Second Primary | 1 | 2021 | 1350 | 0.110 |
Why?
|
| Cancer Care Facilities | 1 | 2017 | 884 | 0.100 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2019 | 1048 | 0.100 |
Why?
|
| Bone Marrow | 2 | 2017 | 2358 | 0.100 |
Why?
|
| Reproducibility of Results | 2 | 2020 | 6009 | 0.100 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2013 | 173 | 0.100 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2019 | 1648 | 0.100 |
Why?
|
| Conjunctiva | 1 | 2013 | 250 | 0.100 |
Why?
|
| Herpes Zoster | 1 | 2011 | 50 | 0.100 |
Why?
|
| Nasal Bone | 1 | 2010 | 19 | 0.100 |
Why?
|
| Spinal Cord Diseases | 1 | 2011 | 90 | 0.100 |
Why?
|
| Combined Modality Therapy | 5 | 2021 | 8865 | 0.090 |
Why?
|
| Carcinoma | 2 | 2020 | 2578 | 0.090 |
Why?
|
| Bone Neoplasms | 2 | 2021 | 2576 | 0.090 |
Why?
|
| Papillomavirus Infections | 1 | 2019 | 980 | 0.090 |
Why?
|
| Radiopharmaceuticals | 2 | 2013 | 1301 | 0.090 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2019 | 1249 | 0.090 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2013 | 1226 | 0.090 |
Why?
|
| Wernicke Encephalopathy | 1 | 2008 | 12 | 0.080 |
Why?
|
| Pharynx | 2 | 2019 | 153 | 0.080 |
Why?
|
| Multiple Myeloma | 2 | 2018 | 2138 | 0.080 |
Why?
|
| Rare Diseases | 1 | 2011 | 351 | 0.080 |
Why?
|
| Nose Neoplasms | 1 | 2010 | 229 | 0.080 |
Why?
|
| Intracranial Hemorrhages | 1 | 2009 | 121 | 0.080 |
Why?
|
| Nose Diseases | 1 | 2007 | 10 | 0.080 |
Why?
|
| Incidence | 5 | 2020 | 5673 | 0.080 |
Why?
|
| Hernia | 1 | 2007 | 46 | 0.080 |
Why?
|
| Surgical Flaps | 1 | 2014 | 927 | 0.080 |
Why?
|
| Pineal Gland | 1 | 2007 | 50 | 0.080 |
Why?
|
| Neoplasm Staging | 3 | 2019 | 13658 | 0.080 |
Why?
|
| Nasolacrimal Duct | 1 | 2007 | 53 | 0.080 |
Why?
|
| Follow-Up Studies | 4 | 2021 | 14889 | 0.080 |
Why?
|
| Child | 5 | 2020 | 29154 | 0.070 |
Why?
|
| Neoplasms | 3 | 2019 | 15193 | 0.060 |
Why?
|
| Melanoma | 1 | 2021 | 5317 | 0.060 |
Why?
|
| Survival Rate | 2 | 2020 | 12221 | 0.060 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2009 | 5319 | 0.050 |
Why?
|
| Stroke | 1 | 2009 | 1144 | 0.050 |
Why?
|
| Prognosis | 4 | 2021 | 21713 | 0.050 |
Why?
|
| Breast Neoplasms | 2 | 2021 | 15694 | 0.040 |
Why?
|
| Radioimmunotherapy | 1 | 2019 | 119 | 0.040 |
Why?
|
| Cervical Vertebrae | 1 | 2019 | 205 | 0.040 |
Why?
|
| Biopsy | 2 | 2017 | 3443 | 0.040 |
Why?
|
| Tertiary Healthcare | 1 | 2017 | 44 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2021 | 2231 | 0.030 |
Why?
|
| Incidental Findings | 1 | 2017 | 272 | 0.030 |
Why?
|
| Treatment Outcome | 3 | 2019 | 32848 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2021 | 899 | 0.030 |
Why?
|
| Survivors | 1 | 2021 | 1031 | 0.030 |
Why?
|
| Remission Induction | 1 | 2021 | 3569 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2019 | 9244 | 0.030 |
Why?
|
| Global Health | 1 | 2017 | 657 | 0.030 |
Why?
|
| Methylprednisolone | 1 | 2011 | 193 | 0.020 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2013 | 375 | 0.020 |
Why?
|
| Immunoglobulins | 1 | 2011 | 266 | 0.020 |
Why?
|
| Child, Preschool | 2 | 2019 | 16273 | 0.020 |
Why?
|
| Chemoradiotherapy | 1 | 2019 | 1946 | 0.020 |
Why?
|
| Lung Neoplasms | 2 | 2009 | 11538 | 0.020 |
Why?
|
| Exanthema | 1 | 2011 | 211 | 0.020 |
Why?
|
| Confusion | 1 | 2008 | 31 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2013 | 2307 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2011 | 461 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2021 | 3341 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2009 | 495 | 0.020 |
Why?
|
| Survival Analysis | 2 | 2009 | 9180 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2009 | 756 | 0.020 |
Why?
|
| Age Distribution | 1 | 2009 | 698 | 0.020 |
Why?
|
| Probability | 1 | 2009 | 866 | 0.020 |
Why?
|
| Leiomyosarcoma | 1 | 2008 | 223 | 0.020 |
Why?
|
| Reference Values | 1 | 2009 | 1099 | 0.020 |
Why?
|
| Uterine Neoplasms | 1 | 2008 | 545 | 0.020 |
Why?
|
| Smoking | 1 | 2013 | 2440 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 6207 | 0.010 |
Why?
|
| Tumor Burden | 1 | 2009 | 1987 | 0.010 |
Why?
|
| United States | 1 | 2020 | 15433 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2010 | 3981 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2017 | 12873 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2013 | 10001 | 0.010 |
Why?
|
| Registries | 1 | 2009 | 2170 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2009 | 5112 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2009 | 6869 | 0.010 |
Why?
|
| Risk Factors | 1 | 2008 | 17523 | 0.010 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2008 | 6915 | 0.010 |
Why?
|